Sheppard Mullin Advised Instem in Acquisition of Xybion
The firm represented ArchiMed-backed Instem in its acquisition of Xybion Digital from Banerjee Group. Instem is a leading supplier of SaaS platforms across discovery, study management, regulatory submission and clinical trial analytics. Xybion is best known for its Pristima™ preclinical study management platform. Like Instem, Xybion has primarily focused on serving life sciences customers, particularly CROs, Pharma and Biotechnology firms.
The combination allows Instem to meet the needs of all life sciences users in preclinical study management. Financial terms were not disclosed.
The Sheppard Mullin deal team that represented Instem was led by partners Valerie Demont and Matt McCalip and associates Teresita Acedo and Edouard Goguillon. Invaluable assistance was provided by partners Niya Tang, Dmitry Chelnitsky, Daniel Yannuzzi, Sean Kirby, Townsend Bourne, Reid Whitten, Jared Nagley and Carolyn Metnick, special counsels Malika Levarlet and Sally Elshihabi, and associates Julien Blanquart, Theo Mayer, Michael Weisshar, Iman Naieem, Cortney Inman, Michael Sutton, Daniel Alvarado and Sidrah Amin.
Read the press release here.
Attorneys
- Teresita Acedo
- Daniel J. Alvarado
- Julien Blanquart
- Townsend L. Bourne
- Dmitriy Chelnitsky
- Valérie Demont
- Sally Elshihabi
- Edouard Goguillon
- Cortney Inman
- Sean J. Kirby
- Malika Levarlet
- Theo Mayer
- Matthew A. McCalip
- Carolyn V. Metnick
- Jared P. Nagley
- Iman Naieem
- Michael D. Sutton
- Niya Tang
- Michael H. Weisshar
- Reid Whitten
- Daniel N. Yannuzzi